Last reviewed · How we verify
NCT03935672: PEARL
PEARL PET-based Adaptive Radiotherapy Clinical Trial
NA trial testing PET-CT scans in Oropharyngeal Cancer in 50 participants. Status unknown.
28 February 2021
Quick facts
| Lead sponsor | Velindre NHS Trust |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 July 2019 |
| Primary completion | 28 February 2021 |
| Estimated completion | 28 February 2023 |
| Sites | 3 locations across United Kingdom |
Drugs / interventions tested
- PET-CT scans
- Outlining the biological GTVs (bGTV_P and bGTV_iP)
- Blood samples for cell-free DNA analysis
- Salivary samples for cell-free DNA analysis
Conditions studied
- Oropharyngeal Cancer — all drugs for Oropharyngeal Cancer →
Sponsor
Velindre NHS Trust
Who can join
18 and older, any sex, with Oropharyngeal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The PEARL study will recruit approximately 50 patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) who are about to undergo primary treatment with concurrent chemo-radiation from South Wales (Velindre Cancer Centre and Singleton Hospital, Swansea) and Bristol. The main aim is to see whether it is feasible to preform a positron emission tomography-computed tomography (PET-CT) scan after 2 weeks of radiotherapy and re-plan the radiotherapy based on this PET-CT scan, to re-distribute the dose of radiotherapy being delivered, so that a smaller area of normal tissues in the mouth and throat are treated to a high dose of radiotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Adaptive radiotherapy for head and neck cancer: Pitfalls and possibilities from the radiation oncologist's point of view.
Nuyts S, Bollen H, Eisbruch A, Strojan P, et al · · 2024 · cited 13× · PMID 38650546 · DOI 10.1002/cam4.7192
Verify or expand the search:
- PubMed search for NCT03935672
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oropharyngeal Cancer
Currently open trials in the same condition.
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06446713 — PIRATES: Image-guided Hyper-fractioned Dose-escalation With Proton Therapy for Head and Neck Cancer · Phase 1 · recruiting
- NCT06747390 — Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery · Phase 1 · recruiting
- NCT05363709 — BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients · Phase 2 · active not recruiting
- NCT05862792 — Liposomal Bupivacaine and Transoral Robotic Surgery · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03935672 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Velindre NHS Trust
- Last refreshed: 2 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03935672.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing